BiotechTube

Grazaoprevir/Elbasavir + Grazaoprevir/Elbasavir/RBV

ApprovedUNKNOWN
1 views this week 0 watching💤 Quiet
Interest: 39/100
39
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Compensated Cirrhosis

Conditions

Compensated Cirrhosis

Trial Timeline

Aug 1, 2018 → Dec 31, 2020

NCT ID
NCT03037151

About Grazaoprevir/Elbasavir + Grazaoprevir/Elbasavir/RBV

Grazaoprevir/Elbasavir + Grazaoprevir/Elbasavir/RBV is a approved stage product being developed by Merck for Compensated Cirrhosis. The current trial status is unknown. This product is registered under clinical trial identifier NCT03037151. Target conditions include Compensated Cirrhosis.

What happened to similar drugs?

2 of 4 similar drugs in Compensated Cirrhosis were approved

Approved (2) Terminated (1) Active (2)
✅telbivudine/LDT600NovartisApproved
✅Telbivudine/LDT600ANovartisApproved
🔄Aliskiren + PlaceboNovartisPhase 3
🔄Albutein 20%GrifolsPhase 3

Hype Score Breakdown

Clinical
20
Activity
4
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT03037151ApprovedUNKNOWN

Competing Products

9 competing products in Compensated Cirrhosis

See all competitors
ProductCompanyStageHype Score
TRV027 Dose #1 + TRV027 Dose #2 + TRV027 Dose #3 + PlaceboTrevenaPhase 2
25
Mesenchymal Stem CellRohto PharmaceuticalPre-clinical
26
Mesenchymal stem cellRohto PharmaceuticalPhase 1/2
32
telbivudine/LDT600NovartisApproved
43
Terlipressin acetate + Serelaxin (RLX030)NovartisPhase 2
35
Aliskiren + PlaceboNovartisPhase 3
40
Telbivudine/LDT600ANovartisApproved
35
BMS-986259Bristol Myers SquibbPhase 2
35
Albutein 20%GrifolsPhase 3
37